Off-Label Drug Promotion On The Agenda For Rep. Waxman, States
Executive Summary
Rep. Henry Waxman, D-Calif., is taking a closer look at the marketing practices of five pharmaceutical companies, a probe that follows several state lawsuits over off-label drug promotion
You may also be interested in...
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach
Off-Label Dissemination May Be Clarified – Indirectly – By FDAAA Regs
Issues surrounding off-label dissemination may be clarified through regulations required by the FDA Amendments Act of 2007